Science 37, a trailblazing company focused on “site-less” clinical trials, announced today $29 million in Series C funding led by Glynn Capital Management with participation from GV. The round included new strategic investments from Amgen Ventures, as well as participation from all existing investors Lux Capital, Redmile Group, dRx Capital (a Qualcomm and Novartis joint…

Without clinical trials, new medicine may never make it from the research lab to patients in need. These carefully designed studies can provide important data that include proper dosage, benefit to patients, and potential side effects. There is a growing challenge, however, in finding appropriate participants, especially for treatments that target highly specific conditions affecting narrower patient populations. Right now, there are more than 40,000 clinical studies recruiting patients in the U.S. alone, with some…

Health 2.0 Conferences are the leading showcase of cutting-edge innovation that's transforming health and health care. They present the best minds, technologies and resources in compelling panels, discussions, and live product demonstrations worldwide.

(Science Launch with Dr. Noah Craft Co-founder and CEO of Science 37 - courtesy of New York Times DealBook Conference) Two weeks ago, I was presented with a great opportunity to speak amongst some very distinguished individuals at the New York Times DealBook Conference. In a modern world of instant gratification, this conference gave some innovators the chance to come together and speak of long term visions or goals. With Science 37, we're combining technology advances that have…

LOS ANGELES, Oct. 18, 2016 /PRNewswire/ -- Science 37 (http://www.science37.com), a technology-enabled clinical research company, today announced that it has completed a $31 million Series B financing. Science 37 is reimagining clinical research by bringing clinical trials to people's homes, which unlocks access to those beyond a geographical barrier. The investment will help the company grow operations, further develop its novel technology platform and continue to expand into new therapeutic areas. The Series B financing was…

I’m just back from DPharm 2016 in Boston, where I had the pleasure of kicking off this year’s DPharm Idol competition.  DPharm Idol is where a select group of companies present what they believe to be a disruptive service or technology to the traditional clinical trial process.  As last year's DPharm Idol  “Disruptive Innovator of the Year,” I was given the honor of presenting this year’s companies and providing an update on what Science 37…

Leading skin microbiome company AOBiome announced today the launch of its Phase 2B trial using its first-in-class live bacteria to treat acne.  Phase 2B marks the advancement from the company's successful Phase 1B/2A dose-ranging safety study, which resulted in no serious adverse events and no difference in adverse events between treatment and vehicle groups. The Phase 2B trial is being jointly conducted with Science 37, a clinical research organization applying breakthrough telemedicine-based approach to bring…

There’s no denying that it’s a new era in medicine. Stakeholders across the healthcare system are shifting business models to focus on value. Entities that were once competitors are now working together to open data and share resources. And patients, previously siloed from their own health care decision making, are becoming true partners in care. But with all of the promise also come challenges. The evolution of research, technology and policies will take time. And…

Zit, pimple, blemish, overly large red spot right in the middle of your face before a big event, these are all different ways we describe the same nemesis….acne! From those pre-pubescent days to sometimes into adulthood, we’ve all experienced waking up to acne. But do you know how they even come to be? What exactly does your body go through to produce one of these sprouting marks of annoyance? Our skin is covered in little…

At the heart of faster cures and better treatments is clinical research. It is the process through which new drugs, medical devices and biologics are brought to market. It is the way in which we advance medicine to deliver improvements in care and hope for a healthier tomorrow.

There is no denying that technology has transformed nearly every aspect of our daily lives – from how we communicate, to the way we travel, to the process through which we make decisions. Indeed, even regulated industries, typically slow to move and resistant to change, have begun to embrace disruption

Science 37 (http://science37.com), a technology-enabled clinical research company, today announced the completion of a $6.5 million Series A financing co-led by Lux Capital and dRx Capital. The investment will accelerate Science 37’s development and rollout of its new operating model, which solves some of the greatest inefficiencies in conducting clinical trials.

At the The Conference Forum's DPharm: Disruptive Innovations to Advance Clinical Trials U.S. conference last week, Science 37 was awarded the Disruptive Innovator of the Year award by a panel of judges composed of pharmaceutical industry experts and patient advocates.

Science 37 CEO and Co-Founder Noah Craft, MD, PhD submitted the following comments on the White House website's Precision Medicine Initiative Page.

In honor of World Cancer Day 2015, the Bonnie J. Addario Lung Cancer Foundation and Free To Breathe, with support from Celgene and Genentech, created the Clinical Trial Innovation Prize. The ultimate goal of the challenge is to produce a breakthrough that doubles the accrual rate of lung cancer clinical trials. We couldn’t be happier to have been selected as one of 12 finalists and awarded one of the first three prizes in “Ideation” phase of the program.

LA BioMed and Science 37 have launched their first collaborative clinical research trial and enrolled patients in the first-ever virtual, networked clinical trial using telemedicine to monitor the effects of an infusion medication. The research study will compare the effects of rituximab with another medication called mycophenolate mofetil in treating adults with active pemphigus vulgaris (PV). Pemphigus vulgaris is an auto-immune skin condition that causes your skin to form blisters. LA Biomed is one of more than 60 sites for the PEMPHIX clinical trial, sponsored by Genentech, and the only telemedicine-based site.